繁體
简体中文
繁體中文

深 滬

undefined undefined

--

NaN.000

NaN.00%

华盛通華盛通
立即下載
  • 最 高--
  • 今 開--
  • 振 幅 NaN.00%
  • 最 低 --
  • 昨 收 --
  • 成交額 --

個股概要

財務分析

公司資料

相關新聞

分紅派息

  • 分時圖
  • 日k
  • 周k
  • 月k

相關新聞

更多
  • Tyson Foods Announces Updates to Board of Directors

    Tyson Foods announced board changes, appointing Les R. Baledge as Lead Independent Director, Sudhanshu Priyadarshi as a new independent director on the Audit Committee, and naming Olivia Tyson and John Randal Tyson as Vice Chairs. Barbara A. Tyson and Mike Beebe will retire in February 2027. These changes reflect the company's commitment to long-term growth and governance.

    11-19 22:00

  • Chemomab Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update

    Chemomab Therapeutics Ltd. announced progress toward its proposed merger with Scipher Medicine, including the completion of a Type B Pre-IND interaction with the FDA for nebokitug in rheumatoid arthritis (RA). The merger, expected to close in Q1 2027, aims to create a precision medicine company leveraging Scipher's AI-powered platform and Chemomab's anti-CCL24 antibody. A special shareholder meeting is scheduled for December 4, 2026, to vote on t...

    11-19 13:00

  • Allarity Therapeutics Granted U.S. Patent for Stenoparib’s Clinical Dosing Regimen, with Protection Into 2045

    Allarity Therapeutics has been granted a U.S. patent (No. 12,806,205) covering stenoparib's twice-daily dosing regimen, with protection extending into 2045. The patent includes 36 claims for treating ovarian cancer and other solid tumors, as well as patients resistant to prior therapies. Stenoparib, a dual PARP and WNT pathway inhibitor, is being developed for advanced ovarian and other cancers. The patent strengthens intellectual property suppor...

    11-18 12:50

  • Espey Mfg. & Electronics Corp. reports first quarter results 

    Espey Mfg. & Electronics Corp. reported Q1 fiscal 2027 results with net sales of $10.6 million, up from $9.1 million in Q1 2026. Net income was $2.19 million ($0.77 per share), slightly down from $2.17 million ($0.80 per share) in the prior year. Backlog decreased to $126.7 million from $141.1 million, while new orders fell to $2.6 million from $10.5 million. CEO David O’Neil highlighted strong revenue growth and emphasized focus on execution, co...

    11-13 21:05

  • Tyson Foods and Allied Beef Company Announce Plans to Establish a Long-Term Partnership to Strengthen Domestic Cattle Supply

    Tyson Foods announced a new long-term partnership with Allied Beef Company to strengthen the domestic cattle supply chain and support beef production. The collaboration aims to create a more sustainable model for ranchers and increase beef production. Tyson Foods plans to fully reopen the second production shift at its Amarillo facility by summer 2027, boosting production and creating jobs. The partnership reflects Tyson's commitment to investing...

    11-09 14:00

  • 安进(AMGN.US)Q3电话会:上调全年营收与EPS指引 管理层预计IMDELLTRA一线放量将非常迅速

    本次电话会最受关注的问题不是超预期的幅度,而是IMDELLTRA(塔拉塔单抗)在ESMO大会上公布的一线维持治疗数据。

    11-04 09:26

  • Season’s Eatings: Tyson® Debuts New Holiday Nuggets

    <p>Tyson Foods has introduced festive-shaped chicken nuggets, including reindeer, trees, and gingerbread men, available nationwide at major retailers through the end of the year. These holiday nuggets, made with 100% white meat chicken and 12 grams of protein per serving, can be quickly prepared in an air fryer, oven, or microwave. Angela Klinger, GM of Tyson Foods, highlights the product's aim to add fun and convenience to holiday meals. For mor...

    11-02 13:00

  • Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms

    Eton Pharmaceuticals has launched ET-900, a new program evaluating mecasermin (IGF-1) for treating infantile and epileptic spasms. The company licensed patent rights from Baylor College of Medicine for IGF-1 use in spasms. Preclinical research showed IGF-1 therapy reduced spasms in animals. An IND application for a Phase 2 study in children with refractory epileptic spasms has been submitted to the FDA, with dosing planned for Q1 2027. Eton retai...

    11-02 11:50

  • Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026

    Eton Pharmaceuticals, Inc. will report third quarter 2026 financial results on November 5, 2026. Management will host a conference call and live audio webcast at 4:30 p.m. ET, with links provided for participants and webcast access. Investors can submit questions via email to investorrelations@etonpharma.com. An archived webcast will be available on Eton’s website for 30 days. Eton focuses on developing treatments for rare diseases, with twelve a...

    10-29 10:50

  • Callan JMB Advances IV Bag Manufacturing Facility with Projected $450 Million in Annual Revenue

    Callan JMB Inc. has received approval for a $16 million IV bag manufacturing facility at the Atlas Complex in Marion, Alabama. The facility is expected to generate $450 million in annual revenue, supporting U.S. healthcare supply-chain resilience and domestic pharmaceutical production. The project incorporates automation and advanced distribution capabilities, aligning with Callan JMB’s strategy to enhance medical preparedness and strengthen nati...

    10-20 12:00